“Tralokinumab Demonstrated a Consistent Safety Profile With up to 42 Months of Treatment in Moderate to Severe Atopic Dermatitis: Including Adverse Events of Special Interest”. SKIN The Journal of Cutaneous Medicine 7, no. 2 (March 13, 2023): s143. Accessed May 17, 2025. https://skin.dermsquared.com/skin/article/view/2027.